The Oxford-based biotechnology company Theolytics has been awarded €8 million in non-dilutive grant funding from Horizon ...
Adding a minimally invasive laser procedure to immunotherapy achieved dramatically improved survival in a small study of patients with recurrent high-grade astrocytoma, an aggressive brain cancer with ...
Pending final negotiation, grant will fund up to 20 patients in the OCTOPOD-IV Phase 2a expansion study of THEO-260 in platinum-resistant ovarian cancerCompetitive funding award highlights Theolytics’ ...
Memorial Sloan Kettering Cancer Center investigators and collaborators have tested rezatapopt, an oral p53 reactivator ...
Low dose alnodesertib plus gemcitabine met the primary endpoint of progression-free survival (PFS) versus gemcitabine alone in patients with platinum-resistant high-grade serous ovarian cancerStudy ...
(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer trials in progress session and a presentation by Dr. Laurence Albiges discussing REJOICE-PanTumor01, a phase 2 signal-seeking ...
Acrivon Therapeutics (NASDAQ:ACRV) hosted a webcast featuring a key opinion leader (KOL) panel focused on the company’s ...
A new study published in the Journal of the American Medical Association revealed that the chance of developing serous ovarian cancer was shown to be reduced by almost 80% when ...
cDepartment of Obstetrics and Gynaecology, Skåne University Hospital (SUS), Lund University, Sweden dDepartment of Women's and Children's Health, Karolinska Institute, Department of Pelvic Cancer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results